Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced that the first Affimer-based rapid test strips to detect SARS-COV-2 spike protein have been developed and evaluated by

In 2003, the outbreak of severe acute respiratory syndrome (SARS) became the first pandemic of the 21st century and exemplified the rapid rate at which a virus can spread internationally.

Avacta Group plc, which is the developer of Affimer biotherapeutics and reagents, announced that collaborative work with the Centre for Virus Research at the University of Glasgow has shown that

Avacta Group plc (LON:AVCT), the developer of Affimer biotherapeutics and reagents, has announced that collaborative work with the Centre for Virus Research at the University of Glasgow has shown that Affimer reagents

A transatlantic alliance between Avacta in Cambridge UK and Adeptrix  in Massachusetts has accelerated progress of a new diagnostic test for coronavirus. A BAMS™ (bead-assisted mass spectrometry) diagnostic test for

Avacta Group plc (LON:AVCT), the developer of Affimer biotherapeutics and reagents, has announced that a BAMSTM diagnostic test for the COVID-19 infection, being developed with its partner Adeptrix (Beverly MA, USA),

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, today announced in response to substantial institutional interest, its intention to raise gross proceeds of up to £45 million by means

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has today announced offers for subscription via PrimaryBid of new ordinary shares of 10p each in the Company at an issue price

Legal experts at Walker Morris advised life sciences company Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, as it entered into an exclusive distribution agreement with Medusa19 Limited for